Evolution of the Average Target: Actinium Pharmaceuticals, Inc.

Evolution of the Target Price: Actinium Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Actinium Pharmaceuticals, Inc.

4b.YV46zL9fVnEx521AsY3V7lkFAlGKy6InfXXOKq6yiUQ.KykMgdcqJhcF1Dk3hvmXi29uTxzciO5mMRT9TMXq7A9MEQ6Z73JgCwmkIA~27e008f651cf50be9156dfc29bcaa208
08/08/24 B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16 MT
07/08/24 B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16 MT
14/05/24 Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target MT
19/03/24 Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating MT
11/12/23 B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating MT
06/09/23 HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60 MT
15/08/23 HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating MT
02/03/23 B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating MT
21/02/23 William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform MT
31/10/22 HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating MT
31/10/22 B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating MT
08/09/22 Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target MT
25/08/22 B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated MT
13/04/22 Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating MT
03/08/21 Actinium Pharmaceuticals : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating MT
01/04/21 Actinium Pharmaceuticals : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating MT
05/11/20 Actinium Pharmaceuticals : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+236.54%
+14.63%
- - +45.47%
+61.67%
+5.3%
+29.48%
-18.91%
+18.92%
+9.52%
+3.31%
Average +40.59%
Weighted average by Cap. +23.12%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.040USD
Average target price
3.500USD
Spread / Average Target
+236.54%
High Price Target
5.000USD
Spread / Highest target
+380.77%
Low Price Target
2.000USD
Spread / Lowest Target
+92.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Stephens Inc.
Maxim
B. Riley
HSBC
HC Wainwright
William Blair & Co.
Cantor Fitzgerald
Alliance Global Partners
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.040USD
Average target price
3.500USD
Spread / Average Target
+236.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock
  4. Consensus Actinium Pharmaceuticals, Inc.